Woodstock Corp increased its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 2.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 134,130 shares of the biopharmaceutical company’s stock after buying an additional 2,575 shares during the period. Woodstock Corp’s holdings in Pfizer were worth $6,873,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in PFE. Karp Capital Management Corp acquired a new stake in Pfizer during the 3rd quarter worth $27,000. Worth Asset Management LLC acquired a new position in Pfizer in the first quarter valued at $29,000. Delos Wealth Advisors LLC increased its stake in Pfizer by 100.0% in the third quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 400 shares during the period. Legend Financial Advisors Inc. acquired a new position in Pfizer in the third quarter valued at $42,000. Finally, Align Wealth Management LLC acquired a new position in Pfizer in the fourth quarter valued at $45,000. Hedge funds and other institutional investors own 67.62% of the company’s stock.
Pfizer Stock Performance
Shares of PFE opened at $40.10 on Friday. The company has a 50-day moving average of $43.26 and a two-hundred day moving average of $46.03. The company has a current ratio of 1.22, a quick ratio of 1.00 and a debt-to-equity ratio of 0.34. The stock has a market cap of $225.33 billion, a P/E ratio of 7.32, a PEG ratio of 1.33 and a beta of 0.64. Pfizer Inc. has a 12-month low of $39.23 and a 12-month high of $56.32.
Analyst Upgrades and Downgrades
A number of research analysts have commented on PFE shares. Wells Fargo & Company dropped their price objective on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Friday. Bank of America downgraded shares of Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 target price on the stock. in a report on Wednesday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $75.00 target price on shares of Pfizer in a report on Wednesday, February 1st. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and set a $51.00 target price on the stock in a report on Tuesday, February 7th. Finally, Credit Suisse Group lowered their target price on shares of Pfizer from $54.00 to $50.00 and set an “outperform” rating on the stock in a report on Wednesday, February 1st. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $50.38.
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.